<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83568">
  <stage>Registered</stage>
  <submitdate>4/02/2009</submitdate>
  <approvaldate>21/05/2009</approvaldate>
  <actrnumber>ACTRN12609000313235</actrnumber>
  <trial_identification>
    <studytitle>A feasibility study to characterize electrograms in patients undergoing atrial fibrillation ablation</studytitle>
    <scientifictitle>A Feasibility Pilot Study to Characterize Baseline Atrial Electrograms  in Areas Targeted for Cather Ablation in Patients with Atrial Fibrillation Using the NavX System</scientifictitle>
    <utrn />
    <trialacronym>NavX PVI</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A map of fractionated potentials will be used during an atrial fibrillation (AF) ablation to define the area typically ablated during pulmonary vein antrum isolation using the Diagnostic Landmark Map.  The procedure will take no more than 30 minutes.</interventions>
    <comparator>none</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pulmonary vein atrum isolation: disappearance of all local potentials in the areas of the pulmonary vein antrum defined by early activation in sinus rhythm and during coronary sinus (CS) pacing and by the presence of fractionated potentials.  This will be assessed using a circular mapping catheter.</outcome>
      <timepoint>baseline, 3 months, 6 months and 12 months post procedure.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Flouroscopy duration measured by the timer on the flouroscopy machine</outcome>
      <timepoint>at completion of procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Any patient with atrial fibrillation requiring ablation
-able to achieve and maintain stable sinus rhythm during the mapping procedure
-be on therapeutic level of anticoagulation as determined by the physician</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-Patients with left atrial thrombus or heavy echo contrast on trans-esophageal echo (TEE) prior to the procedure as per physician discretion and standard of care
-Chronic atrial fibrillation
- Inadequate anticoagulation as defined in the inclusion criteria.
-Significant underlying pulmonary disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>ON</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>St Jude Medical</primarysponsorname>
    <primarysponsoraddress>Unit 2- 6695 Millcreek Dr., Mississauga, ON, L5N 5R8</primarysponsoraddress>
    <primarysponsorcountry>Canada</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>St Jude Medical</fundingname>
      <fundingaddress>Unit 2- 6695 Millcreek Dr., Mississauga, ON, L5N 5R8</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will use a different ablation technique that involves creating a three dimensional map of the electrical activity of the heart, followed by identification and ablation of the areas of abnormal activity. It is hypothesized that this technique is feasible and effective and will achieve pulmonary vein antrum isolation, while lowering exposure to fluoroscopy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southlake Region Health Center Research Ethics Board (REB)</ethicname>
      <ethicaddress />
      <ethicapprovaldate>11/08/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Yaariv Khaykin</name>
      <address>Southlake Region Health Center, 712 Davis Drive, Suite 105, Newmarket, Ontario, L3Y 8C3</address>
      <phone>+1 905-895-4521</phone>
      <fax />
      <email>y.khaykin@utoronto.ca</email>
      <country>Canada</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Linnea Aasen-Johnston</name>
      <address>Unit 2- 6695 Millcreek Dr., Mississauga, ON, L5N 5R8</address>
      <phone>+1 905-286-4009</phone>
      <fax />
      <email>LAasen-Johnston@sjm.com</email>
      <country>Canada</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Linnea Aasen-Johnston</name>
      <address>Unit 2- 6695 Millcreek Dr., Mississauga, ON, L5N 5R8</address>
      <phone>+1 905-286-4009</phone>
      <fax />
      <email>LAasen-Johnston@sjm.com</email>
      <country>Canada</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>